Cancer patients commonly experience a number of symptoms of disease progression and the side-effects of radiation therapy and adjuvant chemotherapy, which adversely impact on their quality of life (QOL).

Fatigue is one of the most common and debilitating symptom reported by cancer patients and can affect QOL more than pain.

Malnutrition is the most common secondary diagnosis in cancer patients. Even patients who are eating can become malnourished because of specific biochemical and metabolic changes associated with cancer.

Several recent studies have indicated that intravenous (IV) vitamin C alleviates cancer- and chemotherapy-related symptoms, such as fatigue, insomnia, loss of appetite, nausea, and pain. Improvements in physical, role, cognitive, emotional, and social functioning, as well as an improvement in overall health.

The IVHealthClub uses several IV protocols, most notably high dose intravenous vitamin C and other formulations to improve quality of life and survival of oncology patients.

Highly recommended for our cancer patients, it provides high concentrations of ascorbic acid in plasma, it is preferentially toxic to tumor cells and is an angiogenesis inhibitor.

Intravenous high-dose vitamin C (Ascorbic Acid) has recently been studied as a treatment for cancer patients because of its antitumor activity.

Intravenous infusion of high-dose Vitamin C greatly increases plasma ascorbic acid concentration and ascorbic acid exhibits a pro-oxidant activity which can reduce tumor growth in a variety animal models, using hepatoma, pancreatic cancer, colon cancer, sarcoma, leukemia, prostate cancer, and mesothelioma.

Studies from many confirm that ascorbate concentrations sufficient for its cytotoxicity can be attained in vivo treatments (Chen, et al., 2008; Verrax & Calderon, 2009; Du, et al., 2010; Belin, et al., 2009; Yeom, et al., 2009; Pollard, et al., 2010).

By administering IV ascorbic acid to raise the concentration of ascorbic acid in the patient's plasma above a level that is cytotoxic to the cancer tumor cells.

The treatment is based on the fact that cancer cells contain between 10 and 100-fold less of the enzyme Catalase than normal cells. Because of cancer cells unable to convert toxic hydrogen peroxide to non-toxic oxygen and water due to lack of Catalase, they are more susceptible to damage and death when they are exposed to high doses of Vitamin C.

Cancer patients are often depleted of vitamin C, and intravenous Vitamin C provides an efficient means of restoring tissue stores.

IV Vitamin C treatment has been shown to improve quality of life in cancer patients a variety of metrics.

IV Vitamin C treatment reduces inflammation (as measured by c-reactive protein levels) and reduces the production of pro-inflammatory cytokines.

Glutathione does not act as a radioprotector against DNA damage induced by higher dose Xrays rather it acts as a modulator of DNA repair activity (Pujari et al 2009)

In our augmented glutathione formula (radiation recovery) we preload our patients with our special blend of vitamin C, vitamin B5, vitamin B6, vitamin B complex, magnesium, and calcium and followed with 2-4 grams of Glutathione.

In almost all cases treating obvious deficits, Gl health, and other basic needs will be an amazing improvement in the patient’s quality of life and have NO adverse effect on their cancer or cancer treatment.

A significant decline In Glutathione disulfide, cysteine-cystine, and vitamin E status occurs after chemotherapy. Standard Parenteral nutrition formulas do not improve antioxidant status compared with administration of micronutrients alone. Rehydration therapy is helpful in many instances and is not uncommon in offices providing IV therapy.

Acute dehydration due to fever, vomiting, diarrhea can be safely compensated for over a 4 to 8-hour period.

Our drips contain a special blend of vitamin C, vitamin B5, vitamin B6, vitamin B complex, magnesium, and calcium and ondansetron to fight against diarrhea, dehydration, fatigue, nausea and vomiting.

An association between vitamin D levels and prognosis of metastatic colorectal cancer has been suggested ( Ng K,et al. 2008)

The issue of whether higher levels of vitamin D supplementation can improve prognosis in conjunction with chemotherapy was addressed in the randomized, phase II SUNSHINE trial, in which 139 patients with previously untreated metastatic Colon Cancer who were receiving first-line chemotherapy were randomly assigned to high-dose vitamin D3 (8000 international units [IU] daily for two weeks followed by 4000 IU daily) or standard-dose vitamin D3 (400 IU per day)

In a preliminary report presented at the 2017 annual American Society for Clinical Oncology (ASCO) meeting, the group receiving high-dose vitamin D experienced modestly but significantly longer progression free survival (12.4 versus 10.7 months, p = 0.03). A larger confirmatory phase III trial is planned.

Given the benefits of vitamin D repletion in terms of skeletal health and the possibility of better cancer-related outcomes, it seems reasonable to test serum vitamin D levels in patients with newly diagnosed mCRC and to replete those with low levels (serum 25[OH]D <20 ng/mL).

Ask about our high dose Vit D injections. Call us at (513) 507-9677 and make an appointment today.